Protocol for a multinational risk-stratified randomised controlled trial in paediatric Crohn’s disease: methotrexate versus azathioprine or adalimumab for maintaining remission in patients at low or high risk for aggressive disease course

Introduction Immunomodulators such as thiopurines (azathioprine (AZA)/6-mercaptopurine (6MP)), methotrexate (MTX) and biologics such as adalimumab (ADA) are well established for maintenance of remission within paediatric Crohn’s disease (CD). It remains unclear, however, which maintenance medication...

Полное описание

Библиографические подробности

Главные авторы:	Sibylle Koletzko, Richard K Russell, Arie Levine, Dan Turner, Rachel E Harris, Lissy de Ridder, Frank M Ruemmele, Nicholas M Croft, Marina Aloi, Gigi Veereman, Mattias Neyt, Laetitia Bigot
Формат:	Artigo
Язык:	Inglês
Опубликовано:	BMJ Publishing Group 2020-07-01
Серии:	BMJ Open
Online-ссылка:	https://bmjopen.bmj.com/content/10/7/e034892.full
Метки:	Добавить метку Нет меток, Требуется 1-ая метка записи!